Valuation: Nectar Lifesciences Limited

Market Cap 198.73Cr 2.06Cr 1.83Cr 1.71Cr 1.56Cr 2.94Cr 2.98Cr 21Cr 8.03Cr 101.21Cr 7.75Cr 7.58Cr 325.08Cr P/E 2025
-4.53x
P/E 2026 -0.69x
Enterprise Value 74Cr 76.47L 67.92L 63.52L 57.88L 1.09Cr 1.1Cr 7.68Cr 2.97Cr 37Cr 2.87Cr 2.81Cr 120.43Cr EV / Sales 2025
0.64x
EV / Sales 2026 -
Free-Float
44.34%
Yield 2025 *
-
Yield 2026 -
1 day-0.19%
1 week-6.43%
Current month-0.19%
1 month-17.29%
3 months-11.33%
6 months+10.96%
Current year-47.03%
1 week 10.18
Extreme 10.18
11.19
1 month 10.18
Extreme 10.18
12.72
Current year 9.2
Extreme 9.2
20.94
1 year 9.2
Extreme 9.2
22.49
3 years 9.2
Extreme 9.2
56.39
5 years 9.2
Extreme 9.2
56.39
10 years 7.2
Extreme 7.2
56.39
Manager TitleAgeSince
Director of Finance/CFO 68 14/11/2022
Compliance Officer - 01/04/2025
Director TitleAgeSince
Chairman 66 27/06/1995
Director/Board Member 69 11/02/2019
Director/Board Member 75 21/09/2021
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%-6.43% - - 2.13Cr
-1.21%-3.48%+38.20%+111.92% 1,03100Cr
-2.11%-4.45%+39.01%+66.70% 64TCr
-0.35%-1.84%+6.49%+75.55% 46TCr
-1.26%-2.99%+59.27%+39.98% 36TCr
-0.03%-3.96%+23.63%+40.70% 33TCr
-1.58%-0.76%+13.50%+26.44% 27TCr
-2.02%-2.97%-3.25%+9.88% 25TCr
-2.56%+0.86%+37.20%+53.79% 23TCr
-0.67%-1.26%+32.97%+99.46% 18TCr
Average -1.25%-0.36%+27.45%+58.27% 41.82TCr
Weighted average by Cap. -1.35%-0.35%+30.26%+69.41%

Financials

2025 2026
Net sales 1.67TCr 17Cr 15Cr 14Cr 13Cr 25Cr 25Cr 174.33Cr 67Cr 850.69Cr 65Cr 64Cr 2.73TCr -
Net income -113.68Cr -1.18Cr -1.05Cr -98.07L -89.37L -1.68Cr -1.71Cr -12Cr -4.59Cr -58Cr -4.43Cr -4.34Cr -185.96Cr -292.89Cr -3.04Cr -2.7Cr -2.53Cr -2.3Cr -4.33Cr -4.39Cr -31Cr -12Cr -149.17Cr -11Cr -11Cr -479.11Cr
Net Debt 562.27Cr 5.84Cr 5.19Cr 4.85Cr 4.42Cr 8.32Cr 8.44Cr 59Cr 23Cr 286.36Cr 22Cr 21Cr 919.75Cr -125.11Cr -1.3Cr -1.15Cr -1.08Cr -98.35L -1.85Cr -1.88Cr -13Cr -5.05Cr -64Cr -4.88Cr -4.77Cr -204.65Cr
Logo Nectar Lifesciences Limited
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Employees
111
Date Price Change Volume
01/26/01 ₹10.33 -0.19% 3,138
30/26/30 ₹10.35 -3.36% 47,012
29/26/29 ₹10.71 -0.37% 15,661
28/26/28 ₹10.75 -0.19% 5,263
25/26/25 ₹10.77 -1.10% 24,469